Please ensure Javascript is enabled for purposes of website accessibility

Gaithersburg-based FedMed expands access to cancer tests

BioTheranostics Inc., a San Diego-based provider of genomic-based tools for cancer diagnosis, said it signed a contract with Gaithersburg-based FedMed Inc., one of the largest preferred provider organization networks in the United States, to provide access to bioTheranostics’ genomic tests for patients with breast cancer and metastatic cancers.

Financial terms were not disclosed.

Under the agreement, more than 40 million FedMed members have access to bioTheranostics’ advanced molecular diagnostic and predictive cancer tests that allow a more precise and personalized approach to managing cancer.

FedMed’s programs and services are delivered through a network of more than 550,000 physicians, 4,000 hospitals and 60,000 ancillary care providers nationwide.